COVID‐19 infection in myasthenia gravis: Clinical course and outcomes
- 16 June 2023
- journal article
- research article
- Published by Wiley in Muscle & Nerve
- Vol. 68 (2) , 171-175
Abstract
Introduction/Aims: Myasthenia gravis (MG) patients have been predicted to have high rates of coronavirus disease‐2019 (COVID‐19) complications due to frequent involvement of respiratory muscles in MG and frequent use of immunosuppressive therapies. We investigated outcomes of MG patients infected with SARS‐CoV‐2 to identify risk factors for exacerbation and severe disease.Methods: This was a retrospective analysis of 39 MG patients with SARS‐CoV‐2 infection from January March 1, 2020 to October 25, 2021 at Emory University. Patients’ records were queried for demographic data, MG history, and COVID‐19 treatments and hospitalizations.Results: At the time of infection, 8 of 39 were vaccinated, 30 of 39 unvaccinated, and 1 unknown. Average age was 52.6 years. Twenty‐seven patients were receiving immunomodulatory treatments at the time of infection. Thirty‐five of 39 were symptomatic, 21 were hospitalized, and 7 required ventilations. MG exacerbations occurred in 5 and were treated with therapeutic plasma exchange (n = 1), intravenous immunoglobulin (IVIg) (n = 1), and prednisone taper (n = 5). Four hospitalized patients died from COVID‐related lung injuries. No deaths were attributed to MG exacerbation; however, one patient receiving IVIg for MG exacerbation had a pulmonary embolism. There were no deaths in fully vaccinated patients, and only one vaccinated patient was admitted to the intensive care unit.Discussion: High rates of COVID‐19 complications and death were observed in this cohort of MG patients. Some patients with MG and COVID‐19 also had an exacerbation during infection. Further studies are needed to determine whether MG patients are at higher risk for complications than the rest of the population.Keywords
This publication has 15 references indexed in Scilit:
- Predictive factors for a severe course of COVID‐19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survivalEuropean Journal of Neurology, 2021
- Impact of Coronavirus Disease 2019 in a French Cohort of Myasthenia GravisNeurology, 2021
- COVID‐19 in multiple sclerosis patients: susceptibility, severity risk factors and serological responseEuropean Journal of Neurology, 2020
- Myasthenia Gravis and COVID-19: Clinical Characteristics and OutcomesFrontiers in Neurology, 2020
- Myasthenic crisis in COVID-19Journal of the Neurological Sciences, 2020
- Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020MMWR. Morbidity and Mortality Weekly Report, 2020
- COVID-19 and neuromuscular disordersNeurology, 2020
- COVID‐19 in patients with myasthenia gravisMuscle & Nerve, 2020
- Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemicJournal of the Neurological Sciences, 2020
- Myasthenia gravisNeurology, 2000